Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.035 SGD
8.57 M SGD
170.59 M SGD
56.88 M
About HYPHENS PHARMA
Sector
CEO
See Wah Lim
Headquarters
Singapore
Website
Founded
1998
ISIN
SG1EE4000006
FIGI
BBG00KSQBRM1
Hyphens Pharma International Ltd. is an investment holding company, which engages in the provision of pharmaceutical and consumer healthcare products. It operates through the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart and Digital. The Specialty Pharma Principals segment includes marketing and selling specialty pharmaceutical products. The Proprietary Brands segment is involved in the development, distribution, and sale of its own proprietary range of dermatological products and health supplement products. The Medical Hypermart and Digital segment focuses on the wholesale of pharmaceuticals and medical supplies. The company was founded by See Wah Lim in 1998 and is headquartered in Singapore.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 1J5 is 0.285 SGD — it has decreased by −1.72% in the past 24 hours. Watch HYPHENS PHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SGX exchange HYPHENS PHARMA stocks are traded under the ticker 1J5.
1J5 stock has risen by 1.79% compared to the previous week, the month change is a −1.72% fall, over the last year there was no change in HYPHENS PHARMA price.
We've gathered analysts' opinions on HYPHENS PHARMA future price: according to them, 1J5 price has a max estimate of 0.35 SGD and a min estimate of 0.35 SGD. Watch 1J5 chart and read a more detailed HYPHENS PHARMA stock forecast: see what analysts think of HYPHENS PHARMA and suggest that you do with its stocks.
1J5 stock is 1.75% volatile and has beta coefficient of 0.07. Track HYPHENS PHARMA stock price on the chart and check out the list of the most volatile stocks — is HYPHENS PHARMA there?
Today HYPHENS PHARMA has the market capitalization of 89.67 M, it has increased by 3.57% over the last week.
Yes, you can track HYPHENS PHARMA financials in yearly and quarterly reports right on TradingView.
HYPHENS PHARMA is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
1J5 net income for the last half-year is 5.42 M SGD, while the previous report showed 5.00 M SGD of net income which accounts for 8.32% change. Track more HYPHENS PHARMA financial stats to get the full picture.
Yes, 1J5 dividends are paid annually. The last dividend per share was 0.01 SGD. As of today, Dividend Yield (TTM)% is 2.97%. Tracking HYPHENS PHARMA dividends might help you take more informed decisions.
HYPHENS PHARMA dividend yield was 3.02% in 2023, and payout ratio reached 31.05%. The year before the numbers were 3.31% and 30.16% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 26, 2024, the company has 440.00 employees. See our rating of the largest employees — is HYPHENS PHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HYPHENS PHARMA EBITDA is 19.26 M SGD, and current EBITDA margin is 8.08%. See more stats in HYPHENS PHARMA financial statements.
Like other stocks, 1J5 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HYPHENS PHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HYPHENS PHARMA technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HYPHENS PHARMA stock shows the neutral signal. See more of HYPHENS PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.